02171 科濟藥業－Ｂ
按盘价 
15.900 +1.980 (+14.224%) 盈利能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 资产回报率 (%) | -6.601% | -40.615% | -29.792% | -28.468% | -199.367% |
| 股东资金回报率 (%) | -10.637% | -55.845% | -34.986% | -32.624% | -718.562% |
| 资本运用回报率 (%) | -9.006% | -56.245% | -36.283% | -34.426% | -152.237% |
边际利润分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 毛利率 (%) | 63.621% | 37.405% | N/A | N/A | -- |
| 未计利息、税项、折旧及摊销前利润率 (%) | -64.712% | -1913.598% | N/A | N/A | -18142.308% |
| 税前边际利润率 (%) | -81.892% | -2023.554% | N/A | N/A | -18350.358% |
| 纯利率 (%) | -77.876% | -2024.431% | N/A | N/A | -18379.975% |
变现能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 流动比率 (X) | 5.734 X | 6.025 X | 9.546 X | 13.454 X | 7.891 X |
| 速动比率 (X) | 5.699 X | 5.997 X | 9.543 X | 13.454 X | 7.891 X |
财务杠杆分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 总负债 / 总资产比率 (%) | 39.686% | 36.839% | 20.180% | 10.484% | 14.519% |
| 总债项 / 总资产比率 (%) | 4.735% | 9.947% | 3.775% | 4.323% | 9.643% |
| 净债项 / 总资产比率 (%) | -82.208% | -78.458% | -78.173% | -77.768% | -10.076% |
| 总债项 / 股东资金比率 (%) | 7.810% | 15.749% | 4.730% | 4.830% | 11.281% |
| 长期债项 / 股东资金比率 (%) | 6.171% | 12.557% | 3.911% | 3.941% | 3.493% |
| 净债项 / 股东资金比率 (%) | -135.607% | -124.219% | -97.937% | -86.876% | -11.788% |
| 净现金 / (债项) ($) | 10.62亿 | 13.13亿 | 17.65亿 | 21.49亿 | 3.53亿 |
| 每股净现金 / (债项) ($) | 1.863 | 2.296 | 3.065 | 3.752 | 0.622 |
| 总债项 / 资本运用比率 (%) | 5.630% | 11.728% | 4.135% | 4.609% | 10.847% |
| 利息盈利率 (X) | N/A | N/A | N/A | N/A | N/A |
营运效率分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 存货周转率日数 (日) | 56.146日 | 56.270日 | -- | N/A | N/A |
| 应收贸易帐周转率日数 (日) | 35.320日 | 81.175日 | N/A | N/A | N/A |
| 应付贸易帐周转率日数 (日) | N/A | N/A | N/A | N/A | N/A |
| 备注： | 实时报价更新时间为10/03/2026 16:12 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) (千) | RMB -97,861 |
| 增长率 | -87.739% |
| 每股盈利/(亏损) | RMB -0.180 |
| 每股账面资产净值 (¥) | RMB 1.374 |